What is HarborPath?
HarborPath operates as a non-profit entity committed to bridging the gap in healthcare access by providing essential, life-saving medications to uninsured individuals. For over thirteen years, the organization has forged strategic partnerships with pharmaceutical manufacturers, enabling patient assistance programs that ensure access to critical drugs. Beyond medication distribution, HarborPath actively engages in public health education, raising awareness about the dangers of fentanyl and facilitating the widespread availability of Narcan to first responders and educational institutions. Their core mission is to mitigate the financial burden of prescription costs for patients, with a particular focus on oncology treatments and opioid reversal agents.
How much funding has HarborPath raised?
HarborPath has raised a total of $59K across 1 funding round:
Debt
$59K
Debt (2021): $59K with participation from PPP
Key Investors in HarborPath
PPP
Public-Private Partnership
Undisclosed Investors
Undisclosed Investors
What's next for HarborPath?
The recent influx of substantial expansion capital positions HarborPath for significant operational scaling and enhanced program outreach. This strategic investment is expected to bolster their capacity to distribute life-saving medications and broaden their educational initiatives concerning opioid safety. As the organization navigates its Series B/C stage, the focus will likely be on deepening pharmaceutical collaborations, expanding geographic reach for patient assistance programs, and increasing the deployment of Narcan kits and fentanyl awareness resources. This financing underscores a commitment to addressing critical public health needs within underserved populations.
See full HarborPath company page
